
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is poised for a positive financial outlook, with revenue estimates for Trodelvy being raised ahead of its anticipated approval and launch in the second half of 2026, indicating strong market confidence in its oncology pipeline. The company has achieved a significant milestone by hitting its 90% payer coverage goal ahead of schedule, enhancing its revenue potential from the oncology segment, which is critical for diversification amid competitive challenges. Additionally, the robust growth in Gilead's HIV franchise, alongside disciplined operational expenditures and improved operating margins, supports a favorable revenue growth trajectory projected at approximately 4-6% year-on-year for 2026, bolstered by innovations within both the HIV and oncology portfolios.
Bears say
Gilead Sciences has exhibited a concerning trend with its financial performance, particularly highlighted by the substantial reduction in fiscal year 2025 revenue guidance for Veklury from $1.4 billion to $1.0 billion, and an expected decline to $600 million in 2026. The cell therapy segment is also facing challenges, with a reported revenue of $458 million reflecting a 6% year-over-year decrease, and projected to decline further by 10% in 2026 due to ongoing competitive pressures. Additionally, anticipated policy-related headwinds and a $300 million drop in Veklury sales will likely exacerbate revenue weaknesses, diminishing the overall significance of Veklury's contributions to total revenues as they continue to trend downward.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares